Draupnir Bio completes €12 million seed round to progress development of oral small molecule degraders of extracellular proteins Mari YoshiokaJuly 17, 2024
PharmEnable Therapeutics and Sosei Heptares Expand Drug Discovery Collaboration Mari YoshiokaOctober 11, 2023
Sonde Health Partners with GN Group to Research and Develop New Vocal Biomarker Technology to Detect Mild Cognitive Impairment Mari YoshiokaJanuary 18, 2022
F-star Therapeutics Announces Merck KGaA, Darmstadt, Germany Exercises a Fourth Licensing Option in Immuno-Oncology Collaboration Mari YoshiokaJanuary 5, 2022
Korro Bio Completes $116M Series B Financing to Expand the Frontier of Genetic Medicine through its Pipeline of RNA Editing Programs Mari YoshiokaJanuary 5, 2022
LiberoThera Secures 300 Million JPY Financing Agreement with Taiho Ventures Mari YoshiokaAugust 5, 2021
EditForce completed fund raising by third-party allotment and AMED adopts our program Mari YoshiokaJune 30, 2021
LiberoThera Closes 535 Million JPY Financing to Develop GPCR-targeting Therapeutics Mari YoshiokaMay 14, 2021
BIOGEN AND CAPSIGEN ANNOUNCE COLLABORATION TO DISCOVER AND DEVELOP NOVEL AAV CAPSIDS FOR TARGETED CNS AND NEUROMUSCULAR DISORDERS Mari YoshiokaMay 10, 2021
Blacksmith Medicines launches with seed funding and a research collaboration with Lilly Mari YoshiokaJanuary 8, 2021
Ribometrix Announces Collaboration with Genentech to Discover and Develop RNA-Targeted Small Molecule Therapeutics Mari YoshiokaJanuary 6, 2021
F-star Therapeutics Completes Combination with Spring Bank Pharmaceuticals Mari YoshiokaNovember 20, 2020
Korro Bio Closes $91.5 Million Series A Financing to Advance the Next Frontier in RNA Therapeutics Mari YoshiokaSeptember 10, 2020
Spring Bank Pharmaceuticals and F-star Therapeutics Agree to Combine to Pursue Mission of Creating Next Generation Immunotherapies Mari YoshiokaJuly 29, 2020
Merck KGaA, Darmstadt, Germany Takes an Early Option in Immuno-Oncology Collaboration Mari YoshiokaJuly 16, 2020
Sonde Health Launches New Voice-Enabled Health Screening Tool to Help Employers Return to Work During the Global Pandemic Mari YoshiokaJuly 8, 2020
QurAlis raises $42 Million Series A Financing to Develop New Therapies for Amyotrophic Lateral Sclerosis (ALS) Mari YoshiokaMay 13, 2020
FORGE ENTERS INTO COLLABORATION WITH ROCHE TO DEVELOP NOVEL ANTIBIOTIC TO TREAT LUNG INFECTIONS Mari YoshiokaMarch 25, 2020
